All In Biotech

Drug Trial Radar · NCT07301268

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

MC230719 Window of Opportunity Study of GI-102 in Patients With Recurrent High-Grade Glioma

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Aug 3, 2026

Primary completion

Sep 1, 2029

Study completion Sep 1, 2032

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). Glioblastoma is the most common and the most aggressive primary brain tumor in adults. Current standard of care includes surgical resection, radiation and chemotherapy. Treatment is often given before surgery (neoadjuvant therapy) to shrink the tumor and make it easier to remove. Treatment with GI-102, a bispecific fusion protein, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving GI-102 alone and in combination with pembrolizumab between neoadjuvant therapy and surgery may be safe, tolerable, and effective in treating patients with recurrent or progressive IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma.

Conditions

  • Glioblastoma, IDH-Wildtype
  • Progressive Astrocytoma, IDH-Mutant, Grade 4
  • Progressive Glioblastoma
  • Progressive Gliosarcoma
  • Recurrent Astrocytoma, IDH-Mutant, Grade 4
  • Recurrent Glioblastoma, IDH-Wildtype
  • Recurrent Gliosarcoma
  • Resectable Astrocytoma
  • Resectable Glioblastoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102Drug

    Given IV

  • Computed TomographyProcedure

    Undergo CT

  • Echocardiography TestProcedure

    Undergo echocardiography

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • PembrolizumabBiological

    Given IV

  • Surgical ProcedureProcedure

    Undergo surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in pharmacodynamic markers of interest in tumor tissueTime frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.